News About: Pharm. Affairs
Development of oral RA treatments, heated by Korean companies’ patent suits
Development of the Pfizer Pharmaceuticals Korea’s oral rheumatoid arthritis(RA) treatment Xeljanz(generic name: tofacitinib) has been heated.
According to the Intellectual Property Tribunal, the total 12 pharmaceutic...
Hanmi acquires approval of combined treatment for ‘prostatic hypertrophy and erectile dysfunction’
On the 21st, Hanmi Pharm(CEO Gwan-Sun Lee) announced approval to commercialize ‘Gugutams Cap(generic name: tamsulosin 0.4mg+tadalafil 5mg)’ that combines substances for benign prostatic hypertrophy and erectile dysfun...
Leading products shifting generations, ‘Sovaldi’ & ‘Daklinza’
The Korean outpatient prescription market is experiencing a shift in generations. Raising positions in the ranking, Gilead Sciences’ hepatitis C treatment ‘Sovaldi’ and BMS’s ‘Daklinza’ have taken the leading roles in...
Forxiga smile with first PMS result conducted on large Koreans
The post-marketing surveillance(PMS) result of ‘Forxiga(generic name: dapagliflozin),’ a SGLT-2 inhibitor whose research was conducted on 1,500 Korean diabetes type 2 patients, has been released. The 24-week researche...
“CKD and Hanmi had smile in outpatient prescription market”In this 3rd quarter’s outpatient prescription market, it was observed there was fierce competition among pharmaceutical companies.
In the top group, Chong Kun Dang(CKD) and Ha...
|
Who will take Korean distribution licenses for Sovaldi and Harvoni?
The pharmaceutical distribution industry has shown high interests in the Korean distribution licenses of chronic hepatitis C treatments, ‘Sovaldi’ and ‘Harvoni’ that are indicated as products with extremely low margin...
Trade deficits on drugs were increased after Korea-US FTA
After the Korea-US FTA, deficits increased in the healthcare industry. Particularly, deficits in the pharmaceutical industry remained the same.
According to the ‘Healthcare Industry’s Imports and Exports with the U.S...
How much Celltrion’s ‘Remsima’ is prescribed in Europe?It was observed the collective number of patients prescribed for the Celltrion’s autoimmune disease treatment ‘Remsima(U.S. Johnson & Johnson’s ‘Remicade’ biosimilar)’ is about ...
|
Companies including Daewon and Ahngook challeges to ezetimibe complex market
Korean companies are developing fierce competition in the market of complexes having the more powerful function to inhibit cholesterol than the combination of statin and ezetimibe.
They all are planning to launch th...
Shin Poong announces British NICE’s recommendation on Inisia Tab as primary therapy
Shin Poong Pharm(CEO Jae-Man Yoo) announced the National Institute for Health and Clinical Excellence(NICE), a drug cost-efficacy assessment agency under the British government, recommended the national health insuran...
